Compare HIFS & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | HIFS | TECX |
|---|---|---|
| Founded | 1834 | 2019 |
| Country | United States | United States |
| Employees | 97 | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 679.7M | 618.9M |
| IPO Year | N/A | 2018 |
| Metric | HIFS | TECX |
|---|---|---|
| Price | $292.63 | $24.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $75.20 |
| AVG Volume (30 Days) | 30.0K | ★ 180.1K |
| Earning Date | 04-17-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.89% | N/A |
| EPS Growth | N/A | ★ 40.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $248.53 | $14.39 |
| 52 Week High | $338.00 | $39.53 |
| Indicator | HIFS | TECX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 34.26 |
| Support Level | N/A | $17.44 |
| Resistance Level | N/A | $31.39 |
| Average True Range (ATR) | 0.00 | 1.45 |
| MACD | 0.00 | -0.40 |
| Stochastic Oscillator | 0.00 | 2.54 |
Hingham Institution for Savings is a Massachusetts-chartered savings bank headquartered in Hingham, Massachusetts. The bank is principally engaged in the business of commercial and residential real estate mortgage lending, funded by a mix of retail and commercial deposits, wholesale deposits and borrowings. Its primary deposit products are savings, checking, and term certificate accounts, and its primary lending products are residential and commercial mortgage loans secured by properties in eastern Massachusetts. The bank also lends to commercial and residential real estate borrowers and services deposits for customers in the greater Washington, D.C. metropolitan area (WMA) and in the San Francisco Bay Area.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.